This new line of research has made possible the development of products that allow the detection of polymorphisms related to certain pathologies, such as thrombophilia, hemochromatosis, Alzheimer, ...
This new area of research has materialised into two lines of products. On the one hand the RealTyper line includes products exclusive of our company. On the other hand, Thrombo inCode and Cardio inCode products are developed in conjunction with Gendiag and Ferrer inCode company.
This line of research focuses on the obtainment of new products that allow the detection of virus, bacteria, fungi and parasites in a sensitive and effective way. We are currently making great efforts to develop detection systems for bacterial resistances, given that the emergence of antibiotic resistant organisms is a leading health problem.
This line allows the incorporation of new genetic base diseases to our portfolio. Thanks to the integration of New-Generation Sequencing (NGS), we currently perform the diagnosis of hundreds of multigenic diseases through the study of selected genes panels.
Progenie molecular develops computer applications named Visor which facilitate interpretation of the results obtained with RealCycler products (detection and quantification of pathogens) and RealTyper (study of point mutations by genotyping assays for real-time PCR).
We also develop applications that allow the study of mutations by Next-Generation Sequencing (NGS) and arrays. We have also developed the Progestor application, that allows the management of clinical samples and results.
We frequently discover at our lab changes in DNA not previously described before. This gives us the opportunity to carry out a basic research activity which materialises in scientific publications and communications at conferences.
We cooperate with the international scientific community in the registration of these mutations in genetic databases in order to help in the diagnosis of patients all over the world.